GenStorm (“An integrated approach to visualize and model the spatial conformation of genes at the nanoscale level”), led by Pablo Daniel Dans (IRB Barcelona) and Marie Victoire Neguembor (CRG) is one of this projects.
Published in Nature Cell Biology (NCB), the study shows that the EXD2 protein is critical for the mitochondria, the cell’s powerhouses, to produce energy.
This protein was previously thought to be located in the cell nucleus and to be involved in DNA repair.
The results contribute to our basic understanding of mitochondria and suggest that EXD2 could be important for fertility and represent a potential target for cancer therapy.
The programme seeks to stir young people’s interest in science by allowing them to get involved in real projects.
"Crazy About Biomedicine" is part of an initiative run by the Fundación Catalunya - La Pedrera.
This morning Alicante has started the 100xCiencia.2 meeting, which today and tomorrow brings together the vanguard of Spanish research: the Severo Ochoa and María de Maeztu centers of excellence.
The meeting was opened by Carmen Vela, Secretary of State for Research, Development and Innovation, and she highlighted the importance of approaching science and business.
ICREA researcher Roger Gomis, head of the Growth Control and Cancer Metastasis Lab, has recently been awarded a 2016 "Knowledge Industry Grant" (Producte), by the Catalan Government’s Agency for Management of University and Research Grants, for the further development of a therapy for the treatment of breast cancer. His 18-month project, "Lipid targeting in breast cancer", aims to obtain a monoclonal antibody, based on a well-defined molecular target, that is suitable for patient treatment and to complete its pre-clinical development phase.
In an extensive article, the channel of science and technology news Néxt/VózPopuli relates how tycoons in Silicon valley are attempting to buy eternal youth.
Manuel Serrano, researcher at IRB Barcelona, and other experts on ageing consulted, consider that there is an investment “bubble” in the anti-aging research field. “It’s great that wealthy people believe that ageing is a condition that can be treated,” he says. “We are starting to get spectacular results in mice and I think there is a sufficient scientific basis for optimism. If I were rich I would also be investing in this,” he concludes.
Read the article here:...
A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.
Biocat news channel interviews Oscar Flores, co-founder and CEO of Made of Genes. An IRB Barcelona alumnus, Oscar did his PhD in Biomedicine at IRB Barcelona and the Barcelona Supercomputing Center (BSC).
Made of Genes focuses on transactional genomics, helping individuals and companies obtain, store, move, manage and analyse genetic and biomedical data safely and in compliance with legal regulations. Their goal: “For everyone to have their gene sequence in their back pocket and be able to use it every time they go to the doctor,” sums up Oscar Flores.
In the interview, Oscar Flores ...
Roger Gomis, ICREA researcher at IRB Barcelona and founder of Inbiomotion, is one of the five entrepreneurs interviewed in a report published in Ara Emprenem, the supplement of the newspaper ARA. Five companies explain how they have turned their fight against cancer into a business model. Inbiomotion is working on a biomarker to predict bone metastases.
Link to the feature article in ARAEmprenem